nodes	percent_of_prediction	percent_of_DWPC	metapath
Mirabegron—ALB—hematologic cancer	0.111	0.512	CbGaD
Mirabegron—ABCB1—hematologic cancer	0.106	0.488	CbGaD
Mirabegron—SLCO1A2—Chlorambucil—hematologic cancer	0.0497	0.0922	CbGbCtD
Mirabegron—ORM1—Imatinib—hematologic cancer	0.0331	0.0613	CbGbCtD
Mirabegron—BCHE—Triamcinolone—hematologic cancer	0.0237	0.0438	CbGbCtD
Mirabegron—SLCO1A2—Prednisolone—hematologic cancer	0.0188	0.0349	CbGbCtD
Mirabegron—BCHE—Irinotecan—hematologic cancer	0.0179	0.0332	CbGbCtD
Mirabegron—SLCO1A2—Prednisone—hematologic cancer	0.0178	0.0329	CbGbCtD
Mirabegron—ABCB1—Lenalidomide—hematologic cancer	0.0162	0.0301	CbGbCtD
Mirabegron—BCHE—Cisplatin—hematologic cancer	0.0146	0.0271	CbGbCtD
Mirabegron—CYP2D6—Lomustine—hematologic cancer	0.0142	0.0263	CbGbCtD
Mirabegron—ALB—Imatinib—hematologic cancer	0.0139	0.0258	CbGbCtD
Mirabegron—CYP2D6—Idarubicin—hematologic cancer	0.0127	0.0235	CbGbCtD
Mirabegron—SLCO1A2—Dexamethasone—hematologic cancer	0.0111	0.0205	CbGbCtD
Mirabegron—CYP2D6—Hydroxyurea—hematologic cancer	0.0108	0.02	CbGbCtD
Mirabegron—CYP3A4—Bexarotene—hematologic cancer	0.00972	0.018	CbGbCtD
Mirabegron—ABCB1—Daunorubicin—hematologic cancer	0.00951	0.0176	CbGbCtD
Mirabegron—CYP2D6—Bortezomib—hematologic cancer	0.00937	0.0174	CbGbCtD
Mirabegron—ABCB1—Alitretinoin—hematologic cancer	0.00932	0.0173	CbGbCtD
Mirabegron—ALB—Prednisone—hematologic cancer	0.00918	0.017	CbGbCtD
Mirabegron—CYP3A4—Lomustine—hematologic cancer	0.00904	0.0167	CbGbCtD
Mirabegron—CYP3A4—Busulfan—hematologic cancer	0.00904	0.0167	CbGbCtD
Mirabegron—SLCO1A2—Methotrexate—hematologic cancer	0.00891	0.0165	CbGbCtD
Mirabegron—ALB—Irinotecan—hematologic cancer	0.0087	0.0161	CbGbCtD
Mirabegron—CYP3A4—Thiotepa—hematologic cancer	0.00805	0.0149	CbGbCtD
Mirabegron—ABCB1—Imatinib—hematologic cancer	0.00729	0.0135	CbGbCtD
Mirabegron—CYP2D6—Imatinib—hematologic cancer	0.00686	0.0127	CbGbCtD
Mirabegron—ABCB1—Nilotinib—hematologic cancer	0.00662	0.0123	CbGbCtD
Mirabegron—ABCB1—Vinorelbine—hematologic cancer	0.00657	0.0122	CbGbCtD
Mirabegron—CYP3A4—Methoxsalen—hematologic cancer	0.00626	0.0116	CbGbCtD
Mirabegron—CYP2D6—Nilotinib—hematologic cancer	0.00624	0.0116	CbGbCtD
Mirabegron—CYP2D6—Vinorelbine—hematologic cancer	0.00619	0.0115	CbGbCtD
Mirabegron—CYP3A4—Bortezomib—hematologic cancer	0.00596	0.011	CbGbCtD
Mirabegron—ABCB1—Dasatinib—hematologic cancer	0.00585	0.0108	CbGbCtD
Mirabegron—ABCB1—Mitoxantrone—hematologic cancer	0.00578	0.0107	CbGbCtD
Mirabegron—CYP3A4—Daunorubicin—hematologic cancer	0.0057	0.0106	CbGbCtD
Mirabegron—ABCB1—Betamethasone—hematologic cancer	0.00515	0.00955	CbGbCtD
Mirabegron—ABCB1—Gemcitabine—hematologic cancer	0.00511	0.00946	CbGbCtD
Mirabegron—ABCB1—Prednisolone—hematologic cancer	0.00508	0.00942	CbGbCtD
Mirabegron—CYP3A4—Cytarabine—hematologic cancer	0.00503	0.00932	CbGbCtD
Mirabegron—CYP3A4—Teniposide—hematologic cancer	0.00495	0.00918	CbGbCtD
Mirabegron—ABCB1—Prednisone—hematologic cancer	0.0048	0.0089	CbGbCtD
Mirabegron—ALB—Methotrexate—hematologic cancer	0.0046	0.00853	CbGbCtD
Mirabegron—CYP3A4—Ifosfamide—hematologic cancer	0.00457	0.00847	CbGbCtD
Mirabegron—ABCB1—Irinotecan—hematologic cancer	0.00455	0.00843	CbGbCtD
Mirabegron—CYP3A4—Imatinib—hematologic cancer	0.00437	0.00809	CbGbCtD
Mirabegron—CYP3A4—Ruxolitinib—hematologic cancer	0.00411	0.00762	CbGbCtD
Mirabegron—ABCB1—Vinblastine—hematologic cancer	0.00405	0.0075	CbGbCtD
Mirabegron—ABCB1—Vincristine—hematologic cancer	0.00398	0.00737	CbGbCtD
Mirabegron—CYP3A4—Nilotinib—hematologic cancer	0.00397	0.00735	CbGbCtD
Mirabegron—CYP3A4—Vinorelbine—hematologic cancer	0.00393	0.00729	CbGbCtD
Mirabegron—CYP2D6—Vinblastine—hematologic cancer	0.00381	0.00706	CbGbCtD
Mirabegron—ABCB1—Cisplatin—hematologic cancer	0.00371	0.00687	CbGbCtD
Mirabegron—ABCB1—Etoposide—hematologic cancer	0.00364	0.00675	CbGbCtD
Mirabegron—CYP3A4—Triamcinolone—hematologic cancer	0.0036	0.00667	CbGbCtD
Mirabegron—CYP3A4—Dasatinib—hematologic cancer	0.00351	0.0065	CbGbCtD
Mirabegron—CYP3A4—Mitoxantrone—hematologic cancer	0.00346	0.00642	CbGbCtD
Mirabegron—CYP3A4—Betamethasone—hematologic cancer	0.00309	0.00572	CbGbCtD
Mirabegron—CYP3A4—Prednisolone—hematologic cancer	0.00305	0.00564	CbGbCtD
Mirabegron—ABCB1—Dexamethasone—hematologic cancer	0.003	0.00555	CbGbCtD
Mirabegron—CYP3A4—Prednisone—hematologic cancer	0.00288	0.00533	CbGbCtD
Mirabegron—CYP2D6—Dexamethasone—hematologic cancer	0.00282	0.00523	CbGbCtD
Mirabegron—CYP3A4—Irinotecan—hematologic cancer	0.00273	0.00505	CbGbCtD
Mirabegron—ABCB1—Doxorubicin—hematologic cancer	0.00249	0.00461	CbGbCtD
Mirabegron—CYP3A4—Vinblastine—hematologic cancer	0.00242	0.00449	CbGbCtD
Mirabegron—ABCB1—Methotrexate—hematologic cancer	0.00241	0.00446	CbGbCtD
Mirabegron—CYP3A4—Vincristine—hematologic cancer	0.00238	0.00442	CbGbCtD
Mirabegron—CYP2D6—Doxorubicin—hematologic cancer	0.00234	0.00434	CbGbCtD
Mirabegron—CYP3A4—Etoposide—hematologic cancer	0.00218	0.00405	CbGbCtD
Mirabegron—CYP3A4—Dexamethasone—hematologic cancer	0.0018	0.00333	CbGbCtD
Mirabegron—CYP3A4—Doxorubicin—hematologic cancer	0.00149	0.00276	CbGbCtD
Mirabegron—ORM1—hematopoietic system—hematologic cancer	0.000554	0.0884	CbGeAlD
Mirabegron—SLCO1A2—hematopoietic system—hematologic cancer	0.000488	0.0779	CbGeAlD
Mirabegron—ORM1—blood—hematologic cancer	0.000367	0.0585	CbGeAlD
Mirabegron—ORM1—bone marrow—hematologic cancer	0.000355	0.0566	CbGeAlD
Mirabegron—BCHE—hematopoietic system—hematologic cancer	0.000343	0.0548	CbGeAlD
Mirabegron—ORM1—lung—hematologic cancer	0.000321	0.0513	CbGeAlD
Mirabegron—SLCO1A2—lung—hematologic cancer	0.000284	0.0453	CbGeAlD
Mirabegron—SLCO1A2—testis—hematologic cancer	0.000268	0.0427	CbGeAlD
Mirabegron—ALB—testis—hematologic cancer	0.000266	0.0425	CbGeAlD
Mirabegron—CYP3A4—hematopoietic system—hematologic cancer	0.000231	0.0369	CbGeAlD
Mirabegron—CYP2D6—hematopoietic system—hematologic cancer	0.000227	0.0363	CbGeAlD
Mirabegron—BCHE—blood—hematologic cancer	0.000227	0.0363	CbGeAlD
Mirabegron—BCHE—bone marrow—hematologic cancer	0.00022	0.0351	CbGeAlD
Mirabegron—ORM1—lymph node—hematologic cancer	0.00022	0.0351	CbGeAlD
Mirabegron—BCHE—lung—hematologic cancer	0.000199	0.0318	CbGeAlD
Mirabegron—ALB—lymph node—hematologic cancer	0.000193	0.0308	CbGeAlD
Mirabegron—BCHE—testis—hematologic cancer	0.000188	0.03	CbGeAlD
Mirabegron—ABCB1—hematopoietic system—hematologic cancer	0.000164	0.0261	CbGeAlD
Mirabegron—CYP3A4—blood—hematologic cancer	0.000153	0.0244	CbGeAlD
Mirabegron—CYP2D6—blood—hematologic cancer	0.000151	0.024	CbGeAlD
Mirabegron—BCHE—lymph node—hematologic cancer	0.000136	0.0218	CbGeAlD
Mirabegron—CYP2D6—testis—hematologic cancer	0.000125	0.0199	CbGeAlD
Mirabegron—ABCB1—gonad—hematologic cancer	0.000124	0.0198	CbGeAlD
Mirabegron—ABCB1—blood—hematologic cancer	0.000108	0.0173	CbGeAlD
Mirabegron—ABCB1—bone marrow—hematologic cancer	0.000105	0.0167	CbGeAlD
Mirabegron—ABCB1—lung—hematologic cancer	9.5e-05	0.0152	CbGeAlD
Mirabegron—ABCB1—testis—hematologic cancer	8.96e-05	0.0143	CbGeAlD
Mirabegron—ABCB1—lymph node—hematologic cancer	6.5e-05	0.0104	CbGeAlD
Mirabegron—Diarrhoea—Carmustine—hematologic cancer	5.24e-05	0.000276	CcSEcCtD
Mirabegron—Nausea—Bleomycin—hematologic cancer	5.21e-05	0.000274	CcSEcCtD
Mirabegron—Infestation NOS—Epirubicin—hematologic cancer	5.2e-05	0.000274	CcSEcCtD
Mirabegron—Infestation—Epirubicin—hematologic cancer	5.2e-05	0.000274	CcSEcCtD
Mirabegron—Rash—Thiotepa—hematologic cancer	5.2e-05	0.000273	CcSEcCtD
Mirabegron—Dermatitis—Thiotepa—hematologic cancer	5.19e-05	0.000273	CcSEcCtD
Mirabegron—Diarrhoea—Alitretinoin—hematologic cancer	5.19e-05	0.000273	CcSEcCtD
Mirabegron—Headache—Thiotepa—hematologic cancer	5.16e-05	0.000272	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Epirubicin—hematologic cancer	5.16e-05	0.000271	CcSEcCtD
Mirabegron—Hypertension—Dexamethasone—hematologic cancer	5.15e-05	0.000271	CcSEcCtD
Mirabegron—Hypertension—Betamethasone—hematologic cancer	5.15e-05	0.000271	CcSEcCtD
Mirabegron—Diarrhoea—Ifosfamide—hematologic cancer	5.13e-05	0.00027	CcSEcCtD
Mirabegron—Nausea—Vinorelbine—hematologic cancer	5.13e-05	0.00027	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Etoposide—hematologic cancer	5.11e-05	0.000269	CcSEcCtD
Mirabegron—Asthenia—Irinotecan—hematologic cancer	5.11e-05	0.000269	CcSEcCtD
Mirabegron—Asthenia—Mitoxantrone—hematologic cancer	5.11e-05	0.000269	CcSEcCtD
Mirabegron—Fatigue—Etoposide—hematologic cancer	5.1e-05	0.000268	CcSEcCtD
Mirabegron—Dizziness—Carmustine—hematologic cancer	5.06e-05	0.000266	CcSEcCtD
Mirabegron—Constipation—Etoposide—hematologic cancer	5.06e-05	0.000266	CcSEcCtD
Mirabegron—Urinary tract infection—Epirubicin—hematologic cancer	5.06e-05	0.000266	CcSEcCtD
Mirabegron—Rash—Thalidomide—hematologic cancer	5.03e-05	0.000264	CcSEcCtD
Mirabegron—Dermatitis—Thalidomide—hematologic cancer	5.02e-05	0.000264	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Doxorubicin—hematologic cancer	5.02e-05	0.000264	CcSEcCtD
Mirabegron—Dizziness—Alitretinoin—hematologic cancer	5.02e-05	0.000264	CcSEcCtD
Mirabegron—Diarrhoea—Vincristine—hematologic cancer	5e-05	0.000263	CcSEcCtD
Mirabegron—Headache—Thalidomide—hematologic cancer	4.99e-05	0.000263	CcSEcCtD
Mirabegron—Asthenia—Gemcitabine—hematologic cancer	4.97e-05	0.000262	CcSEcCtD
Mirabegron—Dizziness—Ifosfamide—hematologic cancer	4.96e-05	0.000261	CcSEcCtD
Mirabegron—Urinary tract disorder—Methotrexate—hematologic cancer	4.93e-05	0.000259	CcSEcCtD
Mirabegron—Pruritus—Gemcitabine—hematologic cancer	4.91e-05	0.000258	CcSEcCtD
Mirabegron—Vision blurred—Prednisone—hematologic cancer	4.9e-05	0.000258	CcSEcCtD
Mirabegron—Nausea—Thiotepa—hematologic cancer	4.9e-05	0.000258	CcSEcCtD
Mirabegron—Urethral disorder—Methotrexate—hematologic cancer	4.89e-05	0.000257	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Triamcinolone—hematologic cancer	4.89e-05	0.000257	CcSEcCtD
Mirabegron—Sinusitis—Epirubicin—hematologic cancer	4.88e-05	0.000257	CcSEcCtD
Mirabegron—Diarrhoea—Mitoxantrone—hematologic cancer	4.87e-05	0.000256	CcSEcCtD
Mirabegron—Diarrhoea—Irinotecan—hematologic cancer	4.87e-05	0.000256	CcSEcCtD
Mirabegron—Gastrointestinal pain—Etoposide—hematologic cancer	4.84e-05	0.000255	CcSEcCtD
Mirabegron—Infection—Dexamethasone—hematologic cancer	4.84e-05	0.000255	CcSEcCtD
Mirabegron—Infection—Betamethasone—hematologic cancer	4.84e-05	0.000255	CcSEcCtD
Mirabegron—Dizziness—Vincristine—hematologic cancer	4.83e-05	0.000254	CcSEcCtD
Mirabegron—Rash—Carmustine—hematologic cancer	4.83e-05	0.000254	CcSEcCtD
Mirabegron—Dermatitis—Carmustine—hematologic cancer	4.82e-05	0.000254	CcSEcCtD
Mirabegron—Infestation NOS—Doxorubicin—hematologic cancer	4.81e-05	0.000253	CcSEcCtD
Mirabegron—Infestation—Doxorubicin—hematologic cancer	4.81e-05	0.000253	CcSEcCtD
Mirabegron—Headache—Carmustine—hematologic cancer	4.8e-05	0.000252	CcSEcCtD
Mirabegron—Rash—Alitretinoin—hematologic cancer	4.78e-05	0.000252	CcSEcCtD
Mirabegron—Dermatitis—Alitretinoin—hematologic cancer	4.78e-05	0.000251	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Doxorubicin—hematologic cancer	4.77e-05	0.000251	CcSEcCtD
Mirabegron—Tachycardia—Dexamethasone—hematologic cancer	4.76e-05	0.00025	CcSEcCtD
Mirabegron—Tachycardia—Betamethasone—hematologic cancer	4.76e-05	0.00025	CcSEcCtD
Mirabegron—Headache—Alitretinoin—hematologic cancer	4.75e-05	0.00025	CcSEcCtD
Mirabegron—Diarrhoea—Gemcitabine—hematologic cancer	4.74e-05	0.00025	CcSEcCtD
Mirabegron—Nausea—Thalidomide—hematologic cancer	4.74e-05	0.000249	CcSEcCtD
Mirabegron—Dyspepsia—Triamcinolone—hematologic cancer	4.73e-05	0.000249	CcSEcCtD
Mirabegron—Rash—Ifosfamide—hematologic cancer	4.73e-05	0.000249	CcSEcCtD
Mirabegron—Dermatitis—Ifosfamide—hematologic cancer	4.72e-05	0.000248	CcSEcCtD
Mirabegron—Erythema multiforme—Methotrexate—hematologic cancer	4.72e-05	0.000248	CcSEcCtD
Mirabegron—Dizziness—Irinotecan—hematologic cancer	4.71e-05	0.000248	CcSEcCtD
Mirabegron—Urticaria—Etoposide—hematologic cancer	4.7e-05	0.000247	CcSEcCtD
Mirabegron—Rhinitis—Epirubicin—hematologic cancer	4.68e-05	0.000246	CcSEcCtD
Mirabegron—Abdominal pain—Etoposide—hematologic cancer	4.68e-05	0.000246	CcSEcCtD
Mirabegron—Urinary tract infection—Doxorubicin—hematologic cancer	4.68e-05	0.000246	CcSEcCtD
Mirabegron—Eye disorder—Methotrexate—hematologic cancer	4.66e-05	0.000245	CcSEcCtD
Mirabegron—Urticaria—Prednisolone—hematologic cancer	4.64e-05	0.000244	CcSEcCtD
Mirabegron—Asthenia—Cisplatin—hematologic cancer	4.64e-05	0.000244	CcSEcCtD
Mirabegron—Cardiac disorder—Methotrexate—hematologic cancer	4.63e-05	0.000244	CcSEcCtD
Mirabegron—Fatigue—Triamcinolone—hematologic cancer	4.63e-05	0.000244	CcSEcCtD
Mirabegron—Urinary tract disorder—Epirubicin—hematologic cancer	4.61e-05	0.000243	CcSEcCtD
Mirabegron—Rash—Vincristine—hematologic cancer	4.61e-05	0.000242	CcSEcCtD
Mirabegron—Dermatitis—Vincristine—hematologic cancer	4.6e-05	0.000242	CcSEcCtD
Mirabegron—Connective tissue disorder—Epirubicin—hematologic cancer	4.59e-05	0.000241	CcSEcCtD
Mirabegron—Urethral disorder—Epirubicin—hematologic cancer	4.58e-05	0.000241	CcSEcCtD
Mirabegron—Headache—Vincristine—hematologic cancer	4.58e-05	0.000241	CcSEcCtD
Mirabegron—Nausea—Carmustine—hematologic cancer	4.55e-05	0.000239	CcSEcCtD
Mirabegron—Sinusitis—Doxorubicin—hematologic cancer	4.52e-05	0.000238	CcSEcCtD
Mirabegron—Nausea—Alitretinoin—hematologic cancer	4.51e-05	0.000237	CcSEcCtD
Mirabegron—Hypertension—Prednisone—hematologic cancer	4.49e-05	0.000236	CcSEcCtD
Mirabegron—Rash—Mitoxantrone—hematologic cancer	4.49e-05	0.000236	CcSEcCtD
Mirabegron—Rash—Irinotecan—hematologic cancer	4.49e-05	0.000236	CcSEcCtD
Mirabegron—Dermatitis—Mitoxantrone—hematologic cancer	4.48e-05	0.000236	CcSEcCtD
Mirabegron—Dermatitis—Irinotecan—hematologic cancer	4.48e-05	0.000236	CcSEcCtD
Mirabegron—Headache—Mitoxantrone—hematologic cancer	4.46e-05	0.000235	CcSEcCtD
Mirabegron—Headache—Irinotecan—hematologic cancer	4.46e-05	0.000235	CcSEcCtD
Mirabegron—Nausea—Ifosfamide—hematologic cancer	4.45e-05	0.000234	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Betamethasone—hematologic cancer	4.44e-05	0.000233	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	4.44e-05	0.000233	CcSEcCtD
Mirabegron—Arthralgia—Prednisone—hematologic cancer	4.43e-05	0.000233	CcSEcCtD
Mirabegron—Diarrhoea—Cisplatin—hematologic cancer	4.42e-05	0.000233	CcSEcCtD
Mirabegron—Erythema multiforme—Epirubicin—hematologic cancer	4.42e-05	0.000232	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	4.4e-05	0.000231	CcSEcCtD
Mirabegron—Rash—Gemcitabine—hematologic cancer	4.37e-05	0.00023	CcSEcCtD
Mirabegron—Dermatitis—Gemcitabine—hematologic cancer	4.37e-05	0.00023	CcSEcCtD
Mirabegron—Eye disorder—Epirubicin—hematologic cancer	4.37e-05	0.00023	CcSEcCtD
Mirabegron—Headache—Gemcitabine—hematologic cancer	4.34e-05	0.000228	CcSEcCtD
Mirabegron—Nausea—Vincristine—hematologic cancer	4.34e-05	0.000228	CcSEcCtD
Mirabegron—Cardiac disorder—Epirubicin—hematologic cancer	4.34e-05	0.000228	CcSEcCtD
Mirabegron—Rhinitis—Doxorubicin—hematologic cancer	4.33e-05	0.000228	CcSEcCtD
Mirabegron—Dyspepsia—Dexamethasone—hematologic cancer	4.29e-05	0.000226	CcSEcCtD
Mirabegron—Dyspepsia—Betamethasone—hematologic cancer	4.29e-05	0.000226	CcSEcCtD
Mirabegron—Urinary tract disorder—Doxorubicin—hematologic cancer	4.27e-05	0.000225	CcSEcCtD
Mirabegron—Urticaria—Triamcinolone—hematologic cancer	4.27e-05	0.000224	CcSEcCtD
Mirabegron—Asthenia—Etoposide—hematologic cancer	4.25e-05	0.000223	CcSEcCtD
Mirabegron—Connective tissue disorder—Doxorubicin—hematologic cancer	4.25e-05	0.000223	CcSEcCtD
Mirabegron—Urethral disorder—Doxorubicin—hematologic cancer	4.24e-05	0.000223	CcSEcCtD
Mirabegron—Nausea—Mitoxantrone—hematologic cancer	4.23e-05	0.000222	CcSEcCtD
Mirabegron—Nausea—Irinotecan—hematologic cancer	4.23e-05	0.000222	CcSEcCtD
Mirabegron—Infection—Prednisone—hematologic cancer	4.22e-05	0.000222	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Dexamethasone—hematologic cancer	4.21e-05	0.000221	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Betamethasone—hematologic cancer	4.21e-05	0.000221	CcSEcCtD
Mirabegron—Back pain—Methotrexate—hematologic cancer	4.2e-05	0.000221	CcSEcCtD
Mirabegron—Fatigue—Betamethasone—hematologic cancer	4.2e-05	0.000221	CcSEcCtD
Mirabegron—Fatigue—Dexamethasone—hematologic cancer	4.2e-05	0.000221	CcSEcCtD
Mirabegron—Pruritus—Etoposide—hematologic cancer	4.19e-05	0.00022	CcSEcCtD
Mirabegron—Tachycardia—Prednisone—hematologic cancer	4.14e-05	0.000218	CcSEcCtD
Mirabegron—Skin disorder—Prednisone—hematologic cancer	4.12e-05	0.000217	CcSEcCtD
Mirabegron—Nausea—Gemcitabine—hematologic cancer	4.12e-05	0.000217	CcSEcCtD
Mirabegron—Vision blurred—Methotrexate—hematologic cancer	4.1e-05	0.000215	CcSEcCtD
Mirabegron—Erythema multiforme—Doxorubicin—hematologic cancer	4.09e-05	0.000215	CcSEcCtD
Mirabegron—Rash—Cisplatin—hematologic cancer	4.07e-05	0.000214	CcSEcCtD
Mirabegron—Dermatitis—Cisplatin—hematologic cancer	4.07e-05	0.000214	CcSEcCtD
Mirabegron—Diarrhoea—Etoposide—hematologic cancer	4.05e-05	0.000213	CcSEcCtD
Mirabegron—Eye disorder—Doxorubicin—hematologic cancer	4.04e-05	0.000212	CcSEcCtD
Mirabegron—Cardiac disorder—Doxorubicin—hematologic cancer	4.01e-05	0.000211	CcSEcCtD
Mirabegron—Gastrointestinal pain—Dexamethasone—hematologic cancer	3.98e-05	0.00021	CcSEcCtD
Mirabegron—Gastrointestinal pain—Betamethasone—hematologic cancer	3.98e-05	0.00021	CcSEcCtD
Mirabegron—Back pain—Epirubicin—hematologic cancer	3.93e-05	0.000207	CcSEcCtD
Mirabegron—Dizziness—Etoposide—hematologic cancer	3.92e-05	0.000206	CcSEcCtD
Mirabegron—Urticaria—Betamethasone—hematologic cancer	3.87e-05	0.000204	CcSEcCtD
Mirabegron—Urticaria—Dexamethasone—hematologic cancer	3.87e-05	0.000204	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Prednisone—hematologic cancer	3.87e-05	0.000203	CcSEcCtD
Mirabegron—Dizziness—Prednisolone—hematologic cancer	3.86e-05	0.000203	CcSEcCtD
Mirabegron—Asthenia—Triamcinolone—hematologic cancer	3.85e-05	0.000203	CcSEcCtD
Mirabegron—Abdominal pain—Dexamethasone—hematologic cancer	3.85e-05	0.000203	CcSEcCtD
Mirabegron—Abdominal pain—Betamethasone—hematologic cancer	3.85e-05	0.000203	CcSEcCtD
Mirabegron—Nausea—Cisplatin—hematologic cancer	3.84e-05	0.000202	CcSEcCtD
Mirabegron—Vision blurred—Epirubicin—hematologic cancer	3.83e-05	0.000202	CcSEcCtD
Mirabegron—Pruritus—Triamcinolone—hematologic cancer	3.8e-05	0.0002	CcSEcCtD
Mirabegron—Dyspepsia—Prednisone—hematologic cancer	3.74e-05	0.000196	CcSEcCtD
Mirabegron—Rash—Etoposide—hematologic cancer	3.73e-05	0.000196	CcSEcCtD
Mirabegron—Dermatitis—Etoposide—hematologic cancer	3.73e-05	0.000196	CcSEcCtD
Mirabegron—Headache—Etoposide—hematologic cancer	3.71e-05	0.000195	CcSEcCtD
Mirabegron—Arthralgia—Methotrexate—hematologic cancer	3.7e-05	0.000195	CcSEcCtD
Mirabegron—Rash—Prednisolone—hematologic cancer	3.68e-05	0.000194	CcSEcCtD
Mirabegron—Dermatitis—Prednisolone—hematologic cancer	3.68e-05	0.000193	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.67e-05	0.000193	CcSEcCtD
Mirabegron—Fatigue—Prednisone—hematologic cancer	3.66e-05	0.000192	CcSEcCtD
Mirabegron—Headache—Prednisolone—hematologic cancer	3.66e-05	0.000192	CcSEcCtD
Mirabegron—Back pain—Doxorubicin—hematologic cancer	3.64e-05	0.000191	CcSEcCtD
Mirabegron—Constipation—Prednisone—hematologic cancer	3.63e-05	0.000191	CcSEcCtD
Mirabegron—Palpitations—Epirubicin—hematologic cancer	3.59e-05	0.000189	CcSEcCtD
Mirabegron—Dizziness—Triamcinolone—hematologic cancer	3.55e-05	0.000187	CcSEcCtD
Mirabegron—Vision blurred—Doxorubicin—hematologic cancer	3.55e-05	0.000187	CcSEcCtD
Mirabegron—Infection—Methotrexate—hematologic cancer	3.52e-05	0.000185	CcSEcCtD
Mirabegron—Nausea—Etoposide—hematologic cancer	3.52e-05	0.000185	CcSEcCtD
Mirabegron—Hypertension—Epirubicin—hematologic cancer	3.51e-05	0.000185	CcSEcCtD
Mirabegron—Asthenia—Betamethasone—hematologic cancer	3.5e-05	0.000184	CcSEcCtD
Mirabegron—Asthenia—Dexamethasone—hematologic cancer	3.5e-05	0.000184	CcSEcCtD
Mirabegron—Gastrointestinal pain—Prednisone—hematologic cancer	3.47e-05	0.000183	CcSEcCtD
Mirabegron—Nausea—Prednisolone—hematologic cancer	3.47e-05	0.000182	CcSEcCtD
Mirabegron—Arthralgia—Epirubicin—hematologic cancer	3.46e-05	0.000182	CcSEcCtD
Mirabegron—Pruritus—Betamethasone—hematologic cancer	3.45e-05	0.000181	CcSEcCtD
Mirabegron—Pruritus—Dexamethasone—hematologic cancer	3.45e-05	0.000181	CcSEcCtD
Mirabegron—Skin disorder—Methotrexate—hematologic cancer	3.44e-05	0.000181	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.44e-05	0.000181	CcSEcCtD
Mirabegron—Rash—Triamcinolone—hematologic cancer	3.39e-05	0.000178	CcSEcCtD
Mirabegron—Dry mouth—Epirubicin—hematologic cancer	3.39e-05	0.000178	CcSEcCtD
Mirabegron—Dermatitis—Triamcinolone—hematologic cancer	3.38e-05	0.000178	CcSEcCtD
Mirabegron—Urticaria—Prednisone—hematologic cancer	3.37e-05	0.000177	CcSEcCtD
Mirabegron—Headache—Triamcinolone—hematologic cancer	3.36e-05	0.000177	CcSEcCtD
Mirabegron—Abdominal pain—Prednisone—hematologic cancer	3.35e-05	0.000176	CcSEcCtD
Mirabegron—Diarrhoea—Betamethasone—hematologic cancer	3.33e-05	0.000175	CcSEcCtD
Mirabegron—Diarrhoea—Dexamethasone—hematologic cancer	3.33e-05	0.000175	CcSEcCtD
Mirabegron—Palpitations—Doxorubicin—hematologic cancer	3.33e-05	0.000175	CcSEcCtD
Mirabegron—Infection—Epirubicin—hematologic cancer	3.3e-05	0.000173	CcSEcCtD
Mirabegron—Hypertension—Doxorubicin—hematologic cancer	3.25e-05	0.000171	CcSEcCtD
Mirabegron—Tachycardia—Epirubicin—hematologic cancer	3.24e-05	0.00017	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.23e-05	0.00017	CcSEcCtD
Mirabegron—Skin disorder—Epirubicin—hematologic cancer	3.22e-05	0.00017	CcSEcCtD
Mirabegron—Dizziness—Betamethasone—hematologic cancer	3.22e-05	0.000169	CcSEcCtD
Mirabegron—Dizziness—Dexamethasone—hematologic cancer	3.22e-05	0.000169	CcSEcCtD
Mirabegron—Arthralgia—Doxorubicin—hematologic cancer	3.2e-05	0.000168	CcSEcCtD
Mirabegron—Nausea—Triamcinolone—hematologic cancer	3.19e-05	0.000168	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	3.18e-05	0.000167	CcSEcCtD
Mirabegron—Dry mouth—Doxorubicin—hematologic cancer	3.13e-05	0.000165	CcSEcCtD
Mirabegron—Dyspepsia—Methotrexate—hematologic cancer	3.12e-05	0.000164	CcSEcCtD
Mirabegron—Rash—Dexamethasone—hematologic cancer	3.07e-05	0.000162	CcSEcCtD
Mirabegron—Rash—Betamethasone—hematologic cancer	3.07e-05	0.000162	CcSEcCtD
Mirabegron—Dermatitis—Betamethasone—hematologic cancer	3.07e-05	0.000161	CcSEcCtD
Mirabegron—Dermatitis—Dexamethasone—hematologic cancer	3.07e-05	0.000161	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.06e-05	0.000161	CcSEcCtD
Mirabegron—Fatigue—Methotrexate—hematologic cancer	3.06e-05	0.000161	CcSEcCtD
Mirabegron—Headache—Betamethasone—hematologic cancer	3.05e-05	0.000161	CcSEcCtD
Mirabegron—Headache—Dexamethasone—hematologic cancer	3.05e-05	0.000161	CcSEcCtD
Mirabegron—Infection—Doxorubicin—hematologic cancer	3.05e-05	0.00016	CcSEcCtD
Mirabegron—Asthenia—Prednisone—hematologic cancer	3.04e-05	0.00016	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.02e-05	0.000159	CcSEcCtD
Mirabegron—Pruritus—Prednisone—hematologic cancer	3e-05	0.000158	CcSEcCtD
Mirabegron—Tachycardia—Doxorubicin—hematologic cancer	3e-05	0.000158	CcSEcCtD
Mirabegron—Skin disorder—Doxorubicin—hematologic cancer	2.98e-05	0.000157	CcSEcCtD
Mirabegron—Dyspepsia—Epirubicin—hematologic cancer	2.92e-05	0.000154	CcSEcCtD
Mirabegron—Diarrhoea—Prednisone—hematologic cancer	2.9e-05	0.000153	CcSEcCtD
Mirabegron—Gastrointestinal pain—Methotrexate—hematologic cancer	2.9e-05	0.000153	CcSEcCtD
Mirabegron—Nausea—Dexamethasone—hematologic cancer	2.89e-05	0.000152	CcSEcCtD
Mirabegron—Nausea—Betamethasone—hematologic cancer	2.89e-05	0.000152	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.87e-05	0.000151	CcSEcCtD
Mirabegron—Fatigue—Epirubicin—hematologic cancer	2.86e-05	0.00015	CcSEcCtD
Mirabegron—Constipation—Epirubicin—hematologic cancer	2.84e-05	0.000149	CcSEcCtD
Mirabegron—Urticaria—Methotrexate—hematologic cancer	2.82e-05	0.000148	CcSEcCtD
Mirabegron—Dizziness—Prednisone—hematologic cancer	2.81e-05	0.000148	CcSEcCtD
Mirabegron—Abdominal pain—Methotrexate—hematologic cancer	2.8e-05	0.000147	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.8e-05	0.000147	CcSEcCtD
Mirabegron—Gastrointestinal pain—Epirubicin—hematologic cancer	2.71e-05	0.000143	CcSEcCtD
Mirabegron—Dyspepsia—Doxorubicin—hematologic cancer	2.7e-05	0.000142	CcSEcCtD
Mirabegron—Rash—Prednisone—hematologic cancer	2.68e-05	0.000141	CcSEcCtD
Mirabegron—Dermatitis—Prednisone—hematologic cancer	2.67e-05	0.000141	CcSEcCtD
Mirabegron—Headache—Prednisone—hematologic cancer	2.66e-05	0.00014	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.65e-05	0.000139	CcSEcCtD
Mirabegron—Fatigue—Doxorubicin—hematologic cancer	2.65e-05	0.000139	CcSEcCtD
Mirabegron—Urticaria—Epirubicin—hematologic cancer	2.64e-05	0.000139	CcSEcCtD
Mirabegron—Constipation—Doxorubicin—hematologic cancer	2.63e-05	0.000138	CcSEcCtD
Mirabegron—Abdominal pain—Epirubicin—hematologic cancer	2.62e-05	0.000138	CcSEcCtD
Mirabegron—Asthenia—Methotrexate—hematologic cancer	2.54e-05	0.000134	CcSEcCtD
Mirabegron—Nausea—Prednisone—hematologic cancer	2.52e-05	0.000133	CcSEcCtD
Mirabegron—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.51e-05	0.000132	CcSEcCtD
Mirabegron—Pruritus—Methotrexate—hematologic cancer	2.51e-05	0.000132	CcSEcCtD
Mirabegron—Urticaria—Doxorubicin—hematologic cancer	2.44e-05	0.000128	CcSEcCtD
Mirabegron—Abdominal pain—Doxorubicin—hematologic cancer	2.43e-05	0.000128	CcSEcCtD
Mirabegron—Diarrhoea—Methotrexate—hematologic cancer	2.43e-05	0.000128	CcSEcCtD
Mirabegron—Asthenia—Epirubicin—hematologic cancer	2.38e-05	0.000125	CcSEcCtD
Mirabegron—Pruritus—Epirubicin—hematologic cancer	2.35e-05	0.000124	CcSEcCtD
Mirabegron—Dizziness—Methotrexate—hematologic cancer	2.35e-05	0.000123	CcSEcCtD
Mirabegron—Diarrhoea—Epirubicin—hematologic cancer	2.27e-05	0.000119	CcSEcCtD
Mirabegron—Rash—Methotrexate—hematologic cancer	2.24e-05	0.000118	CcSEcCtD
Mirabegron—Dermatitis—Methotrexate—hematologic cancer	2.23e-05	0.000118	CcSEcCtD
Mirabegron—Headache—Methotrexate—hematologic cancer	2.22e-05	0.000117	CcSEcCtD
Mirabegron—Asthenia—Doxorubicin—hematologic cancer	2.2e-05	0.000116	CcSEcCtD
Mirabegron—Dizziness—Epirubicin—hematologic cancer	2.19e-05	0.000115	CcSEcCtD
Mirabegron—Pruritus—Doxorubicin—hematologic cancer	2.17e-05	0.000114	CcSEcCtD
Mirabegron—Nausea—Methotrexate—hematologic cancer	2.11e-05	0.000111	CcSEcCtD
Mirabegron—Diarrhoea—Doxorubicin—hematologic cancer	2.1e-05	0.000111	CcSEcCtD
Mirabegron—Rash—Epirubicin—hematologic cancer	2.09e-05	0.00011	CcSEcCtD
Mirabegron—Dermatitis—Epirubicin—hematologic cancer	2.09e-05	0.00011	CcSEcCtD
Mirabegron—Headache—Epirubicin—hematologic cancer	2.08e-05	0.000109	CcSEcCtD
Mirabegron—Dizziness—Doxorubicin—hematologic cancer	2.03e-05	0.000107	CcSEcCtD
Mirabegron—Nausea—Epirubicin—hematologic cancer	1.97e-05	0.000104	CcSEcCtD
Mirabegron—Rash—Doxorubicin—hematologic cancer	1.94e-05	0.000102	CcSEcCtD
Mirabegron—Dermatitis—Doxorubicin—hematologic cancer	1.93e-05	0.000102	CcSEcCtD
Mirabegron—Headache—Doxorubicin—hematologic cancer	1.92e-05	0.000101	CcSEcCtD
Mirabegron—Nausea—Doxorubicin—hematologic cancer	1.82e-05	9.59e-05	CcSEcCtD
Mirabegron—ABCB1—Metabolism—GSTO1—hematologic cancer	7e-06	0.00015	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CD80—hematologic cancer	6.97e-06	0.00015	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—KIT—hematologic cancer	6.96e-06	0.000149	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PIK3CG—hematologic cancer	6.96e-06	0.000149	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—NRAS—hematologic cancer	6.96e-06	0.000149	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PC—hematologic cancer	6.93e-06	0.000149	CbGpPWpGaD
Mirabegron—ALB—Metabolism—NUP98—hematologic cancer	6.9e-06	0.000148	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—SPHK1—hematologic cancer	6.85e-06	0.000147	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PTPN11—hematologic cancer	6.84e-06	0.000147	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—CREBBP—hematologic cancer	6.7e-06	0.000144	CbGpPWpGaD
Mirabegron—ALB—Metabolism—ADCY7—hematologic cancer	6.7e-06	0.000144	CbGpPWpGaD
Mirabegron—ALB—Metabolism—NCOA3—hematologic cancer	6.7e-06	0.000144	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GBA—hematologic cancer	6.7e-06	0.000144	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—SLC35B2—hematologic cancer	6.7e-06	0.000144	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—IDH1—hematologic cancer	6.67e-06	0.000143	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—MAPK3—hematologic cancer	6.67e-06	0.000143	CbGpPWpGaD
Mirabegron—ALB—Metabolism—NUP214—hematologic cancer	6.65e-06	0.000143	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CREB1—hematologic cancer	6.62e-06	0.000142	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ABCC3—hematologic cancer	6.6e-06	0.000142	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—TXN—hematologic cancer	6.6e-06	0.000142	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GSTO1—hematologic cancer	6.6e-06	0.000142	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—UGT1A1—hematologic cancer	6.58e-06	0.000141	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	6.58e-06	0.000141	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—PIK3CA—hematologic cancer	6.55e-06	0.000141	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—BRAF—hematologic cancer	6.54e-06	0.000141	CbGpPWpGaD
Mirabegron—ALB—Metabolism—MTR—hematologic cancer	6.52e-06	0.00014	CbGpPWpGaD
Mirabegron—ALB—Metabolism—ABCG2—hematologic cancer	6.52e-06	0.00014	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CCL2—hematologic cancer	6.48e-06	0.000139	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—IL6R—hematologic cancer	6.46e-06	0.000139	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—SPHK1—hematologic cancer	6.46e-06	0.000139	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CREBBP—hematologic cancer	6.45e-06	0.000139	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—hematologic cancer	6.45e-06	0.000139	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—SLC22A1—hematologic cancer	6.41e-06	0.000138	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CRABP1—hematologic cancer	6.41e-06	0.000138	CbGpPWpGaD
Mirabegron—ALB—Metabolism—ENO2—hematologic cancer	6.39e-06	0.000137	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—PIK3CD—hematologic cancer	6.36e-06	0.000136	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	6.29e-06	0.000135	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—MTHFR—hematologic cancer	6.26e-06	0.000135	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ALOX5—hematologic cancer	6.24e-06	0.000134	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—hematologic cancer	6.24e-06	0.000134	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—UGT1A1—hematologic cancer	6.2e-06	0.000133	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GSTT1—hematologic cancer	6.2e-06	0.000133	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MAP2K1—hematologic cancer	6.16e-06	0.000132	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—MTAP—hematologic cancer	6.12e-06	0.000132	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PIK3CD—hematologic cancer	6.12e-06	0.000131	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	6.1e-06	0.000131	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—PIK3CA—hematologic cancer	6.06e-06	0.00013	CbGpPWpGaD
Mirabegron—ALB—Metabolism—SDC1—hematologic cancer	6.06e-06	0.00013	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—NUP98—hematologic cancer	6.05e-06	0.00013	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CRABP1—hematologic cancer	6.04e-06	0.00013	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—SLC22A1—hematologic cancer	6.04e-06	0.00013	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—PIK3R1—hematologic cancer	6e-06	0.000129	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PIK3CG—hematologic cancer	6e-06	0.000129	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—KRAS—hematologic cancer	5.99e-06	0.000129	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ALOX5—hematologic cancer	5.88e-06	0.000126	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ADCY7—hematologic cancer	5.87e-06	0.000126	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—NCOA3—hematologic cancer	5.87e-06	0.000126	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—FGF2—hematologic cancer	5.86e-06	0.000126	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—JAK2—hematologic cancer	5.83e-06	0.000125	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—NUP214—hematologic cancer	5.83e-06	0.000125	CbGpPWpGaD
Mirabegron—ALB—Transmembrane transport of small molecules—CREBBP—hematologic cancer	5.8e-06	0.000125	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	5.79e-06	0.000124	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PIK3R1—hematologic cancer	5.78e-06	0.000124	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ABCG2—hematologic cancer	5.71e-06	0.000123	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—MTR—hematologic cancer	5.71e-06	0.000123	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—NUP98—hematologic cancer	5.7e-06	0.000122	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—JAK2—hematologic cancer	5.62e-06	0.000121	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ENO2—hematologic cancer	5.6e-06	0.00012	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—CREBBP—hematologic cancer	5.56e-06	0.000119	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—PIK3CB—hematologic cancer	5.54e-06	0.000119	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—NCOA3—hematologic cancer	5.53e-06	0.000119	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ADCY7—hematologic cancer	5.53e-06	0.000119	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	5.52e-06	0.000119	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—PIK3CA—hematologic cancer	5.5e-06	0.000118	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—NUP214—hematologic cancer	5.49e-06	0.000118	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MDM2—hematologic cancer	5.48e-06	0.000118	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	5.46e-06	0.000117	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—FHL2—hematologic cancer	5.46e-06	0.000117	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GSTT1—hematologic cancer	5.43e-06	0.000117	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ABCG2—hematologic cancer	5.38e-06	0.000116	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—MTR—hematologic cancer	5.38e-06	0.000116	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—AGRN—hematologic cancer	5.35e-06	0.000115	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—AKT1—hematologic cancer	5.35e-06	0.000115	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PIK3CB—hematologic cancer	5.33e-06	0.000115	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MTOR—hematologic cancer	5.33e-06	0.000115	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—SDC1—hematologic cancer	5.31e-06	0.000114	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ENO2—hematologic cancer	5.28e-06	0.000113	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PIK3CD—hematologic cancer	5.27e-06	0.000113	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	5.27e-06	0.000113	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PIK3CG—hematologic cancer	5.26e-06	0.000113	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—ALB—hematologic cancer	5.21e-06	0.000112	CbGpPWpGaD
Mirabegron—ALB—Metabolism—NQO1—hematologic cancer	5.15e-06	0.000111	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CD44—hematologic cancer	5.15e-06	0.000111	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GSTT1—hematologic cancer	5.12e-06	0.00011	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—HRAS—hematologic cancer	5.09e-06	0.000109	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—IL2—hematologic cancer	5.09e-06	0.000109	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	5.08e-06	0.000109	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—IDH2—hematologic cancer	5.07e-06	0.000109	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—HMMR—hematologic cancer	5.07e-06	0.000109	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	5.04e-06	0.000108	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CDKN1B—hematologic cancer	5e-06	0.000107	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—SDC1—hematologic cancer	5e-06	0.000107	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PIK3R1—hematologic cancer	4.98e-06	0.000107	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—AKT1—hematologic cancer	4.95e-06	0.000106	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CASP3—hematologic cancer	4.91e-06	0.000105	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—IL2—hematologic cancer	4.9e-06	0.000105	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—CREBBP—hematologic cancer	4.88e-06	0.000105	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CYCS—hematologic cancer	4.87e-06	0.000105	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—IL6—hematologic cancer	4.87e-06	0.000105	CbGpPWpGaD
Mirabegron—ALB—Metabolism—HSP90AA1—hematologic cancer	4.84e-06	0.000104	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CCND1—hematologic cancer	4.77e-06	0.000103	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ARNTL—hematologic cancer	4.77e-06	0.000102	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—JUN—hematologic cancer	4.76e-06	0.000102	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	4.76e-06	0.000102	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ACP5—hematologic cancer	4.64e-06	9.97e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CA9—hematologic cancer	4.64e-06	9.97e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PIK3CD—hematologic cancer	4.63e-06	9.94e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CDKN1A—hematologic cancer	4.62e-06	9.92e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PTEN—hematologic cancer	4.61e-06	9.9e-05	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PIK3CB—hematologic cancer	4.6e-06	9.87e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NCOR2—hematologic cancer	4.58e-06	9.84e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—ALB—hematologic cancer	4.57e-06	9.81e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—EP300—hematologic cancer	4.57e-06	9.8e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—NQO1—hematologic cancer	4.51e-06	9.69e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CD44—hematologic cancer	4.51e-06	9.69e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MAPK8—hematologic cancer	4.51e-06	9.68e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—AKT1—hematologic cancer	4.5e-06	9.66e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—SRC—hematologic cancer	4.44e-06	9.53e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—EP300—hematologic cancer	4.39e-06	9.44e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PIK3R1—hematologic cancer	4.37e-06	9.38e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—IDH1—hematologic cancer	4.36e-06	9.37e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	4.36e-06	9.36e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—VEGFA—hematologic cancer	4.32e-06	9.29e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—TXN—hematologic cancer	4.31e-06	9.27e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTO1—hematologic cancer	4.31e-06	9.27e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ABCC3—hematologic cancer	4.31e-06	9.27e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GSTP1—hematologic cancer	4.3e-06	9.23e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—SRC—hematologic cancer	4.27e-06	9.18e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—NRAS—hematologic cancer	4.27e-06	9.17e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CYCS—hematologic cancer	4.27e-06	9.17e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CD44—hematologic cancer	4.25e-06	9.13e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—NQO1—hematologic cancer	4.25e-06	9.13e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—HSP90AA1—hematologic cancer	4.24e-06	9.11e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—SPHK1—hematologic cancer	4.22e-06	9.07e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—VEGFA—hematologic cancer	4.16e-06	8.94e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	4.16e-06	8.93e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—STAT3—hematologic cancer	4.12e-06	8.85e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—NRAS—hematologic cancer	4.11e-06	8.83e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—MAPK3—hematologic cancer	4.09e-06	8.78e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—ABCB1—hematologic cancer	4.07e-06	8.73e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—UGT1A1—hematologic cancer	4.06e-06	8.71e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PIK3CB—hematologic cancer	4.03e-06	8.66e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CYCS—hematologic cancer	4.02e-06	8.64e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	4e-06	8.59e-05	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PTEN—hematologic cancer	3.97e-06	8.53e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—TGFB1—hematologic cancer	3.97e-06	8.52e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GSTM1—hematologic cancer	3.95e-06	8.48e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—NCOR1—hematologic cancer	3.95e-06	8.48e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CRABP1—hematologic cancer	3.95e-06	8.48e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—SLC22A1—hematologic cancer	3.95e-06	8.48e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MAPK3—hematologic cancer	3.94e-06	8.46e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ALOX5—hematologic cancer	3.85e-06	8.26e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MYC—hematologic cancer	3.83e-06	8.22e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—TGFB1—hematologic cancer	3.82e-06	8.2e-05	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—EP300—hematologic cancer	3.79e-06	8.14e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GSTP1—hematologic cancer	3.76e-06	8.08e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NUP98—hematologic cancer	3.72e-06	8e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—KRAS—hematologic cancer	3.68e-06	7.89e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ADCY7—hematologic cancer	3.62e-06	7.77e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NCOA3—hematologic cancer	3.62e-06	7.77e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NUP214—hematologic cancer	3.59e-06	7.71e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GSTP1—hematologic cancer	3.55e-06	7.62e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—KRAS—hematologic cancer	3.54e-06	7.6e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ABCG2—hematologic cancer	3.52e-06	7.55e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—MTR—hematologic cancer	3.52e-06	7.55e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—MTHFR—hematologic cancer	3.49e-06	7.49e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PTEN—hematologic cancer	3.49e-06	7.49e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GSTM1—hematologic cancer	3.46e-06	7.43e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—NCOR1—hematologic cancer	3.46e-06	7.43e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ENO2—hematologic cancer	3.45e-06	7.41e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—PIK3CA—hematologic cancer	3.38e-06	7.25e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ABCB1—hematologic cancer	3.36e-06	7.21e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTT1—hematologic cancer	3.35e-06	7.19e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—EP300—hematologic cancer	3.32e-06	7.14e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—SDC1—hematologic cancer	3.27e-06	7.02e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—TP53—hematologic cancer	3.27e-06	7.02e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GSTM1—hematologic cancer	3.26e-06	7e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—NCOR1—hematologic cancer	3.26e-06	7e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PIK3CA—hematologic cancer	3.25e-06	6.98e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—TP53—hematologic cancer	3.15e-06	6.75e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—HRAS—hematologic cancer	3.12e-06	6.71e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.07e-06	6.6e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—MTHFR—hematologic cancer	3.06e-06	6.56e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—HRAS—hematologic cancer	3.01e-06	6.46e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PIK3CG—hematologic cancer	2.93e-06	6.3e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—MTHFR—hematologic cancer	2.88e-06	6.19e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—IL6—hematologic cancer	2.88e-06	6.18e-05	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PIK3CA—hematologic cancer	2.8e-06	6.02e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CD44—hematologic cancer	2.78e-06	5.97e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NQO1—hematologic cancer	2.78e-06	5.97e-05	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—AKT1—hematologic cancer	2.76e-06	5.92e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CREBBP—hematologic cancer	2.72e-06	5.84e-05	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—AKT1—hematologic cancer	2.66e-06	5.7e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CYCS—hematologic cancer	2.63e-06	5.65e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	2.61e-06	5.61e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PIK3CD—hematologic cancer	2.58e-06	5.53e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PIK3CG—hematologic cancer	2.57e-06	5.52e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PIK3CA—hematologic cancer	2.46e-06	5.28e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PIK3R1—hematologic cancer	2.43e-06	5.23e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PIK3CG—hematologic cancer	2.42e-06	5.2e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CREBBP—hematologic cancer	2.38e-06	5.11e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTP1—hematologic cancer	2.32e-06	4.98e-05	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—AKT1—hematologic cancer	2.29e-06	4.92e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PIK3CD—hematologic cancer	2.26e-06	4.85e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PIK3CB—hematologic cancer	2.25e-06	4.82e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CREBBP—hematologic cancer	2.24e-06	4.82e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ALB—hematologic cancer	2.23e-06	4.79e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ABCB1—hematologic cancer	2.2e-06	4.71e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PIK3R1—hematologic cancer	2.13e-06	4.58e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTM1—hematologic cancer	2.13e-06	4.58e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NCOR1—hematologic cancer	2.13e-06	4.58e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PIK3CD—hematologic cancer	2.13e-06	4.57e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ALB—hematologic cancer	2.1e-06	4.51e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PIK3R1—hematologic cancer	2.01e-06	4.31e-05	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—AKT1—hematologic cancer	2.01e-06	4.31e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.97e-06	4.23e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PTEN—hematologic cancer	1.94e-06	4.17e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.88e-06	4.04e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.85e-06	3.98e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—EP300—hematologic cancer	1.85e-06	3.98e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PTEN—hematologic cancer	1.7e-06	3.65e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—EP300—hematologic cancer	1.62e-06	3.48e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PTEN—hematologic cancer	1.6e-06	3.44e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.58e-06	3.4e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—EP300—hematologic cancer	1.53e-06	3.28e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.47e-06	3.15e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.39e-06	2.99e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ALB—hematologic cancer	1.37e-06	2.95e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PIK3CA—hematologic cancer	1.37e-06	2.94e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.31e-06	2.82e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.21e-06	2.6e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PIK3CA—hematologic cancer	1.2e-06	2.58e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.13e-06	2.43e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—AKT1—hematologic cancer	1.12e-06	2.4e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PTEN—hematologic cancer	1.05e-06	2.25e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—EP300—hematologic cancer	9.99e-07	2.15e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—AKT1—hematologic cancer	9.8e-07	2.1e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—AKT1—hematologic cancer	9.24e-07	1.98e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PIK3CA—hematologic cancer	7.39e-07	1.59e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—AKT1—hematologic cancer	6.04e-07	1.3e-05	CbGpPWpGaD
